Belzutifan in Europe: A New Targeted Therapy for Clear Cell Renal Cancer
- PMID: 40382295
- DOI: 10.1016/j.eururo.2025.04.009
Belzutifan in Europe: A New Targeted Therapy for Clear Cell Renal Cancer
Abstract
The recent European Medicines Agency marketing authorisation for belzutifan offers patients with renal cell carcinoma a well-tolerated and effective option for third- and fourth-line treatment. Future studies will assess its efficacy in earlier disease stages.
Copyright © 2025. Published by Elsevier B.V.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
